论文部分内容阅读
目的观察异基因外周血造血干细胞移植(allo-PBSCT)治疗骨髓增生异常综合征(MDS)的疗效。方法对23例 MDS 患者行 HLA 相合的同胞间 allo-PBSCT,供者外周血采集前给予G-CSF 动员。输注外周血单个核细胞8.25(4.50～22.36)×10~8/kg,CD34~+细胞5.59(1.57～12.22)×lO~6/kg 移植物抗宿主病(GVHD)的预防给予环孢菌素 A 加短疗程甲氨蝶呤,移植后1天(+1天)～+28天给予霉酚酸酯。结果 23例患者中22例造血完全重建。中性粒细胞>1.0×10~9/L 和 BPC>50 × 10~9/L 的时间分别为+13(+11～+17)天和+30(+13～+102)天。移植相关死亡2例,移植后复发3例,现18例存活。 Kaplan-Meier 分析显示无病生存率、复发率分别为(77.8±8.7)%和(14.4±7.5)%。结论 Allo-PBSCT 治疗 MDS 治愈率高,复发率低。
Objective To observe the effect of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) on myelodysplastic syndrome (MDS). Methods Twenty-three patients with MDS underwent HLA-identical sibling allo-PBSCT. G-CSF mobilization was performed before donor peripheral blood collection. Infusion of peripheral blood mononuclear cells 8.25 (4.50 ~ 22.36) × 10 ~ 8 / kg, CD34 ~ + cells 5.59 (1.57 ~ 12.22) × lO ~ 6 / kg graft versus host disease (GVHD) Methotrexate is added as a shortened course of treatment and mycophenolate mofetil is administered 1 day (+1 day) to +28 days after transplantation. Results Twenty-two of 23 patients underwent complete reconstructions of hematopoiesis. Neutrophils> 1.0 × 10 ~ 9 / L and BPC> 50 × 10 ~ 9 / L were +13 (+11 ~ +17) days and +30 (+13 ~ +102) days respectively. Transplant-related death in 2 cases, 3 cases of recurrence after transplantation, 18 cases are alive. Kaplan-Meier analysis showed a disease-free survival rate of (77.8 ± 8.7)% and (14.4 ± 7.5)%, respectively. Conclusion Allo-PBSCT treatment of MDS high cure rate, recurrence rate is low.